The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Abstract Two-related studies are presented here, detailing our early experience with benzodiazepine-dependent patients treated with a four-day flumazenil infusion using a novel delivery technique. Patients with long-term benzodiazepine dependence who attended the Australian Medical Procedures Research Foundation (AMPRF, Perth, Australia) for treatment were recruited for these studies. Self-reported psychological and physical symptoms, as well as objective vital signs data were collected at intervals before, during and 2 weeks postinfusion. Study A is a case series with cardiovascular measures; study B is an open trial that tracks the psychological profiles of 13 subjects. Withdrawal symptoms were tracked, however, the nature and severity of these symptoms differed between patients. No major complications or discomfort prompting study dropout was observed. Significant benzodiazepine abstinence occurred with this flumazenil infusion method despite high levels of initial dependence, comorbid substance use and comorbid psychiatric illness. Low-dose flumazenil infusion appears to be a safe and effective treatment resulting in withdrawal symptoms of lesser severity than any other cessation method currently available. Recommendations for future research are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
FRESCO, D. M., COLES, M. E., HEIMBERG, R. G., LIEBOWITZ, M. R., HAMI, S., STEIN, M. B., & GOETZ, D. (2001) · Psychological Medicine · doi:10.1017/s0033291701004056 · Cited by 874
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 2×
“Management of benzodiazepine dependence usually involves either progressive withdrawal or abrupt discontinuation, with switching to a longer half-life benzodiazepine or adjunctive medications having a more limited evidence base (Ashton, 2005; Denis, et al., 2006).”
BackgroundWithdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367 · cited 2×
“Soon after their introduction, reports of benzodiazepine dependency emerged (Hollister, et al., 1961), supported by later studies in animals (Petursson and Lader, 1981b) and humans (Covi, et al., 1973; Lader, 1983).”
BackgroundWithdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170 · cited 5×
“Between 15 and 44% of chronic benzodiazepine users become dependent and experience moderate to severe withdrawal symptoms upon cessation (Ashton, 1991; de las, et al., 2000), including emergent anxiety and depressive symptoms (Ashton, 1991; Petursson and Lader, 1981a).”
BackgroundMethodInfluentialLENGTH OF TREATMENT WITH ANXIOLYTIC SEDATIVES AND RESPONSE TO THEIR SUDDEN WITHDRAWAL
Covi, L., Lipman, R. S., Pattison, J. H., Derogatis, L. R., & Uhlenhuth, E. H. (1973) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1973.tb04398.x · Cited by 162
Cuevas, C. D. L., Sanz, E. J., Fuente, J. A. D. L., Padilla, J., & Berenguer, J. C. (2000) · Addiction · doi:10.1046/j.1360-0443.2000.95224511.x · Cited by 153
Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C. (2002) · Addiction Biology · doi:10.1080/1355621021000005973 · Cited by 82
Ali, N. J., & Olsen, R. W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00664.x · Cited by 67 · cited 2×
“Third, it can upregulate GABA-A receptors (Jazvinscak, et al., 2008) and facilitate coupling of the GABA-A and benzodiazepine (BZD) receptor complexes, potentially reversing the downregulation/uncoupling that occurs with long-term benzodiazepine misuse (Ali and Olsen, 2001).”
Background
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“A flumazenil infusion has also been shown to be a safe and effective treatment for benzodiazepine withdrawal (Hood et al., 2009) (III).”
BackgroundKingston, R. E. F., Marel, C., & Mills, K. L. (2017) · Drug and Alcohol Review · doi:10.1111/dar.12448 · Cited by 187
Benzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Self-citationBenzodiazepine dependence: Focus on withdrawal syndrome
Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A. A., Vennat, B., Llorca, P.-M., & Eschalier, A. (2009) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2009.07.001 · Cited by 79
Metadata
- Authors
- Hood, S., O’Neil, G., & Hulse, G.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-01-22
- Volume
- 23
- Issue
- 4
- Pages
- 401-409
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2058825773
- Cited by
- 48
- References
- 11
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. https://app.cochat.ai/papers/10.1177/0269881108100322
- The paper
- Hood, S., O’Neil, G., & Hulse, G. (2009). The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. Journal of Psychopharmacology. https://doi.org/10.1177/0269881108100322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.